Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 20/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | YES1 | P07947 | 1/20 | 0.47 |
| ▸ | LYN | P07948 | 1/20 | 0.47 |
| ▸ | FGR | P09769 | 1/20 | 0.47 |
| ▸ | SRC | P12931 | 1/20 | 0.47 |
| ▸ | PRKCA | P17252 | 1/20 | 0.47 |
| ▸ | FLT3 | P36888 | 1/20 | 0.47 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.47 |
| ▸ | MAP3K9 | P80192 | 1/20 | 0.47 |
| ▸ | PAK5 | Q9P286 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16202691 | 0.92 | SYK (0.52) | SYK | |
| SCHEMBL16194610 | 0.90 | SYK (0.51) | SYKKCNH2JAK2LCKYES1 | |
| SCHEMBL10251527 | 0.89 | SYK (0.40) | SYKKCNH2JAK2LCKYES1 | |
| SCHEMBL16195031 | 0.81 | SYK (0.52) | SYKKCNH2JAK2LCKYES1 | |
| SCHEMBL16202733 | 0.80 | SYK (0.66) | SYKKCNH2JAK2LCKYES1 | |
| SCHEMBL10250504 | 0.80 | SYK (0.46) | SYKKCNH2JAK2LCKYES1 | |
| SCHEMBL10285290 | 0.79 | SYK (0.57) | SYKKCNH2JAK2LCKYES1 | |
| SCHEMBL10250862 | 0.79 | SYK (0.44) | SYKKCNH2JAK2LCKYES1 | |
| SCHEMBL10250835 | 0.79 | SYK (0.46) | SYKKCNH2JAK2LCKYES1 | |
| SCHEMBL16202670 | 0.78 | JAK3 (0.41) | SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140323418-A1 | SELECTIVE KINASE INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2014-10-30 | — | — | US | disclosed |
| US-20140323418-A1 | SELECTIVE KINASE INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2014-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323418-A1 | SELECTIVE KINASE INHIBITORS | SYK, BTK, LCK | SYK 1/4885KCNH2 3642/4885JAK2 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.